Metiamide treatment in five patients with Zollinger-Ellison syndrome.
Five patients with Zollinger-Ellison syndrome received metiamide per os in doses ranging from 600 to 1,200 mg/day for a minimum period of 2 weeks. Drug produced an inhibition of basal gastric acid secretion ranging from 5 to 100% with relief of symptoms. Survey of patients during and after metiamide course showed sometimes a prolonged antisecretory effect up to 26 days after the end of treatment or, on the contrary, a reduced drug activity in spite of increasing doses.
D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D005755:Gastrins / Q000097:blood; D006801:Humans; D008297:Male; D008785:Metiamide / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D012636:Secretory Rate / Q000187:drug effects; D013890:Thiourea / Q000031:analogs & derivatives*; D013997:Time Factors; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy* / Q000503:physiopathology
D005755:Gastrins; D008785:Metiamide; D013890:Thiourea